{"id":"https://openalex.org/W4394599299","doi":"https://doi.org/10.1212/wnl.0000000000206094","title":"Inhibition of TNFalpha Release by Purine Nucleosides in a Human Monocyte-derived Microglial Model Exhibits Apparent Insensitivity to Adenosine, P2X, and P2Y Receptor Antagonism (P5-14.020)","display_name":"Inhibition of TNFalpha Release by Purine Nucleosides in a Human Monocyte-derived Microglial Model Exhibits Apparent Insensitivity to Adenosine, P2X, and P2Y Receptor Antagonism (P5-14.020)","publication_year":2024,"publication_date":"2024-04-09","ids":{"openalex":"https://openalex.org/W4394599299","doi":"https://doi.org/10.1212/wnl.0000000000206094"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000206094","doi":"https://doi.org/10.1212/wnl.0000000000206094","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.0000000000206094","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079719651","display_name":"Omar Qureshi","orcid":"https://orcid.org/0000-0002-2268-4648","observed_orcids":["https://orcid.org/0000-0002-2268-4648"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Omar Qureshi","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000628081","display_name":"Jamie Cowley","orcid":"https://orcid.org/0000-0002-1860-3139","observed_orcids":["https://orcid.org/0000-0002-1860-3139"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jamie Cowley","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100681523","display_name":"Arshpreet Kaur","orcid":"https://orcid.org/0000-0001-6997-2711","observed_orcids":["https://orcid.org/0000-0001-6997-2711"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arshpreet Kaur","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002387059","display_name":"Ashley Pegg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ashley Pegg","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5094221735","display_name":"Leila Sallie","orcid":"https://orcid.org/0009-0009-8644-0536","observed_orcids":["https://orcid.org/0009-0009-8644-0536"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leila Sallie","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067227943","display_name":"Ines Morano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ines Morano","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054387157","display_name":"Neale J Harrison","orcid":"https://orcid.org/0000-0001-6821-4089","observed_orcids":["https://orcid.org/0000-0001-6821-4089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neale Harrison","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083719483","display_name":"Hujo Chan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hujo Chan","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100382254","display_name":"Zhi Li","orcid":"https://orcid.org/0000-0002-0583-1116","observed_orcids":["https://orcid.org/0000-0002-0583-1116"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhi Li","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Emma Welsh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Emma Welsh","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mark Bryant","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Bryant","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084509242","display_name":"Catherine Brady","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Catherine Brady","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061157286","display_name":"John Gordon","orcid":"https://orcid.org/0000-0002-9781-9842","observed_orcids":["https://orcid.org/0000-0002-9781-9842"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Gordon","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102884365","display_name":"Nicholas M. Barnes","orcid":"https://orcid.org/0000-0003-4624-9672","observed_orcids":["https://orcid.org/0000-0003-4624-9672"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicholas Barnes","raw_affiliation_strings":["Celentyx Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celentyx Ltd","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"102","issue":"17_supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.951200008392334,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.951200008392334,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.04430000111460686,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10196","display_name":"Pain Mechanisms and Treatments","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tnf-alpha-release","display_name":"TNF-alpha release","score":0.8289999961853027},{"id":"https://openalex.org/keywords/purinergic-signaling","display_name":"purinergic signaling","score":0.8830000162124634},{"id":"https://openalex.org/keywords/p2x7-receptor","display_name":"P2X7 receptor","score":0.8640000224113464},{"id":"https://openalex.org/keywords/adenosine-receptors","display_name":"adenosine receptors","score":0.7099999785423279},{"id":"https://openalex.org/keywords/purine-nucleosides","display_name":"purine nucleosides","score":0.7990000247955322},{"id":"https://openalex.org/keywords/microglia","display_name":"microglia","score":0.7559999823570251},{"id":"https://openalex.org/keywords/neuroinflammation","display_name":"neuroinflammation","score":0.8610000014305115},{"id":"https://openalex.org/keywords/nlrp3-inflammasome","display_name":"NLRP3 inflammasome","score":0.8830000162124634},{"id":"https://openalex.org/keywords/atp","display_name":"ATP","score":0.5680000185966492},{"id":"https://openalex.org/keywords/bzatp","display_name":"BzATP","score":0.9660000205039978},{"id":"https://openalex.org/keywords/p2y-receptors","display_name":"P2Y receptors","score":0.6570000052452087},{"id":"https://openalex.org/keywords/anti-inflammatory-pathways","display_name":"anti-inflammatory pathways","score":0.6399999856948853},{"id":"https://openalex.org/keywords/lps-priming","display_name":"LPS priming","score":0.6460000276565552},{"id":"https://openalex.org/keywords/purinergic-receptor-antagonists","display_name":"purinergic receptor antagonists","score":0.7440000176429749}],"concepts":[{"id":"https://openalex.org/C57306754","wikidata":"https://www.wikidata.org/wiki/Q1010629","display_name":"Purinergic receptor","level":3,"score":0.7954840660095215},{"id":"https://openalex.org/C2776991684","wikidata":"https://www.wikidata.org/wiki/Q190012","display_name":"Adenosine","level":2,"score":0.6777729392051697},{"id":"https://openalex.org/C2779830541","wikidata":"https://www.wikidata.org/wiki/Q1622829","display_name":"Microglia","level":3,"score":0.6467901468276978},{"id":"https://openalex.org/C2777383412","wikidata":"https://www.wikidata.org/wiki/Q4770891","display_name":"Antagonism","level":3,"score":0.6444833874702454},{"id":"https://openalex.org/C160225129","wikidata":"https://www.wikidata.org/wiki/Q6591687","display_name":"P2Y receptor","level":4,"score":0.5983105897903442},{"id":"https://openalex.org/C172590197","wikidata":"https://www.wikidata.org/wiki/Q17165723","display_name":"Purinergic signalling","level":5,"score":0.5812478065490723},{"id":"https://openalex.org/C2776476023","wikidata":"https://www.wikidata.org/wiki/Q188261","display_name":"Purine","level":3,"score":0.5389090180397034},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.5302120447158813},{"id":"https://openalex.org/C2781184567","wikidata":"https://www.wikidata.org/wiki/Q107244","display_name":"Monocyte","level":2,"score":0.4779355823993683},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4594806432723999},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4557255804538727},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.41725271940231323},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.40318402647972107},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39984118938446045},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.37169304490089417},{"id":"https://openalex.org/C67907053","wikidata":"https://www.wikidata.org/wiki/Q356147","display_name":"Adenosine receptor","level":4,"score":0.37124305963516235},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.30518829822540283},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.276428759098053},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.19526132941246033},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.15289756655693054},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.06567168235778809},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000206094","doi":"https://doi.org/10.1212/wnl.0000000000206094","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.0000000000206094","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9789000153541565}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4390191598","https://openalex.org/W2116854644","https://openalex.org/W1996964000","https://openalex.org/W112051727","https://openalex.org/W1973585961","https://openalex.org/W2074954865","https://openalex.org/W4362665684","https://openalex.org/W2048025558","https://openalex.org/W2464388442","https://openalex.org/W7043361973"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"understand":[2],"the":[3,9,55,97,100,145,203,238,251,258,282,456,517],"impact":[4,56],"of":[5,11,40,43,57,88,96,114,130,144,212,218,227,250,304,318,338,352,365,379,392,406,420,433,447,458,479,493,507,519,544],"purinergic":[6,58,115],"signaling":[7],"on":[8,62],"regulation":[10],"pro-inflammatory":[12,136],"cytokine":[13,124,140],"release":[14,64,141,153,170,208,229,278],"in":[15,85,150,167,224,265,287,325,455,516,539],"human":[16,66,79],"microglia.":[17],"Background:":[18],"Genetic":[19],"evidence":[20],"has":[21,295,309,323,329,343,356,370,383,397,411,424,438,451,470,484,498,512,537,547],"associated":[22,24,134],"microglial":[23],"genes":[25],"(e.g.":[26,137],"TREM2,":[27],"CD33,":[28],"ABCA7":[29],"and":[30,60,120,220],"CR1)":[31],"with":[32,110,117,135],"neurological":[33,288],"disease":[34,289],"implicating":[35],"neuroinflammation":[36],"as":[37,301,315,335,349,362,376,389,403,417,430,444,462,476,490,504,523],"a":[38,86,148,164,185,225,246,272,463],"driver":[39],"pathogenesis.":[41],"Activation":[42],"anti-inflammatory":[44,187,204,248],"pathways":[45],"may":[46,280],"potentially":[47],"bring":[48],"therapeutic":[49,285],"benefit.":[50],"The":[51,94,157,542],"present":[52],"study":[53],"investigated":[54],"agonists":[59,119],"antagonists":[61,121,199,263],"TNFa":[63,152],"from":[65,69,78,551],"microglia":[67,74],"derived":[68],"monocytes":[70,82,102],"(iMDM).":[71],"Design/Methods:":[72],"Human":[73],"(iMDM)":[75],"were":[76,103,108],"differentiated":[77],"peripheral":[80],"blood":[81],"by":[83,105,176,192,209],"culture":[84],"cocktail":[87],"CNS-associated":[89],"cytokines":[90],"over":[91],"5\u201310":[92],"days.":[93],"immuno-phenotype":[95],"iMDM":[98,107],"versus":[99],"originating":[101],"assessed":[104],"immunocytochemistry.":[106],"primed":[109],"LPS":[111],"before":[112],"stimulation":[113],"receptors":[116],"selected":[118],"to":[122,230,257],"investigate":[123],"release.":[125],"Results:":[126],"Although":[127],"high":[128,210],"concentrations":[129,211,217],"ATP":[131,213,219],"are":[132],"generally":[133],"IL-1\u03b2,":[138],"IL-18)":[139],"through":[142],"activation":[143],"P2X7":[146,159,178,252,261],"receptor,":[147],"reduction":[149,166],"LPS-evoked":[151,168],"was":[154,173,190],"also":[155,222],"evident.":[156],"more":[158],"receptor-selective":[160],"agonist":[161],"BzATP":[162,221],"evoked":[163,184],"similar":[165,186],"TNF\u03b1":[169,207,228,277],"although":[171],"this":[172,266],"not":[174,201],"reversed":[175],"selective":[177],"or":[179,214,528],"P2Y":[180],"receptor":[181,194,198,253,262],"antagonists.":[182,195],"Adenosine":[183],"effect,":[188],"which":[189],"blocked":[191],"adenosine":[193,197],"However":[196],"did":[200],"prevent":[202],"effect":[205],"upon":[206],"BzATP.":[215],"High":[216],"resulted":[223],"sensitivity":[226],"NLRP3":[231],"inflammasome":[232],"inhibition":[233],"suggesting":[234],"potential":[235,247,283],"cross-talk":[236],"between":[237],"two":[239],"seemingly":[240],"disparate":[241],"pathways.":[242],"These":[243,269],"findings":[244,270],"suggest":[245,271],"role":[249],"that":[254,279],"is":[255],"insensitive":[256],"small":[259],"molecule":[260],"used":[264],"study.":[267],"Conclusions:":[268],"previously":[273],"undescribed":[274],"pathway":[275],"regulating":[276],"have":[281],"for":[284,299,313,333,347,360,374,387,401,415,428,442,460,465,474,488,502,521,533],"targeting":[286],"involving":[290],"neuoinflammation.":[291],"Disclosure:":[292],"Dr.":[293,307,321,395,422,449,468],"Qureshi":[294,308,322],"received":[296,310,330,344,357,371,384,398,412,425,439,452,471,485,499,513,548],"personal":[297,311,331,345,358,372,385,399,413,426,440,453,472,486,500,514],"compensation":[298,312,332,346,359,373,386,400,414,427,441,454,473,487,501,515],"serving":[300,314,334,348,361,375,388,402,416,429,443,461,475,489,503,522],"an":[302,316,336,350,363,377,390,404,418,431,445,477,491,505,524],"employee":[303,317,337,351,364,378,391,405,419,432,446,478,492,506],"Celentyx":[305,339,366,393,407,434,466,480,494,508,540],"Ltd.":[306,340,367,394,408,435,467,481,495,509,541],"UCB":[319],"Pharma.":[320],"stock":[324,538],"Celentyx.":[326,380,421,448],"Mr.":[327,354,409],"Cowley":[328],"Miss":[341,436],"Kaur":[342],"Celentyx.Ltd.":[353],"Pegg":[355],"Ms.":[368,381],"Sallie":[369],"Morano":[382],"Harrison":[396],"Chan":[410],"Li":[423],"Welsh":[437],"Bryant":[450],"range":[457,518],"$10,000-$49,999":[459,520],"Consultant":[464],"Brady":[469],"Prof.":[482,496,510,535,545],"Gordon":[483],"Barnes":[497,511,536,546],"Editor,":[525,527],"Associate":[526],"Editorial":[529],"Advisory":[530],"Board":[531],"Member":[532],"Frontiers.":[534],"institution":[543],"research":[549],"support":[550],"MRC.":[552]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2024-04-10T00:00:00"}